Tesofensine: what the research shows
- By Reed Calder
- Last reviewed Nov 11, 2026
- 27 studies and official documents checked
In short
Tesofensine is a pill, not a peptide. It blocks the brain’s reuptake of noradrenaline, dopamine and serotonin, and it cuts appetite. In one 24-week trial of 203 adults on a diet, the 0.5 mg dose produced a weight loss 9.2 percentage points greater than placebo, and raised heart rate by 7.4 beats a minute. That trial carries a Lancet expression of concern: Danish inspectors raised concerns about it, and the sponsor said they covered how adverse events were collected and reported. A 372-person phase 3 trial in Mexico has been reported only in company releases, and Mexico has not approved the drug. It isn’t approved anywhere we found, and it is banned in competition in sport.
EvidenceCellAnimalHuman
Tesofensine is sold online as capsules, often called a “peptide” or a research chemical, for weight loss. This page covers what it is, what the obesity trials found, the problems with the 2008 trial, what the combination with a heart drug showed, the safety signals, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Tesofensine, NS2330, NS-2330 | A small-molecule drug, not a peptide: it has no chain of amino acids (PubChem). NS2330 was its developer’s code name (Hauser et al., 2007) | Yes |
| Tesofensine citrate | A salt form with a registry record of its own (PubChem). The trial reports we read don’t say which form was used | Unclear |
| Tesomet | Tesofensine combined with metoprolol, a beta-blocker, to blunt the rise in heart rate (Huynh et al., 2022) | Yes: small trials |
| “Tesofensine peptide” | A search phrase and a sales label. Tesofensine is a small molecule (PubChem) | Same as tesofensine |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The base and the citrate have different registry numbers.
What tesofensine is
Neurons pass signals with chemicals such as noradrenaline, dopamine and serotonin, and then pull the chemicals back in, a step called reuptake. Tesofensine blocks that step for all three, so more of each stays active in the brain (Astrup et al., 2008). In rats and mice it quieted a set of feeding-promoting neurons in the hypothalamus, and it caused more weight loss in obese rats than in lean ones (Perez et al., 2024).
It was first tested for Alzheimer’s and Parkinson’s disease. In 261 people with early Parkinson’s it did no better than placebo (Hauser et al., 2007), but weight loss showed up in those trials. In four of them, 740 people on tesofensine and 228 on placebo, weight over 14 weeks fell 2.8% on 1.0 mg a day and rose 0.5% on placebo (Astrup et al., 2008). That led to obesity trials.
It stays in the body a long time. A model from an Alzheimer’s trial put its half-life at 234 hours, about 10 days (Lehr et al., 2007). In a 2026 study, traces showed in urine for up to 500 hours (Krug et al., 2026).
What has been studied
In people with obesity
- The 2008 phase 2 trial. 203 adults with a body-mass index of 30 to 40, at five Danish centres, were put on a calorie-restricted diet and given a capsule once a day for 24 weeks: tesofensine 0.25 mg (52 people), 0.5 mg (50), 1.0 mg (49) or placebo (52). Placebo lost 2.0%. The three tesofensine groups lost 4.5%, 9.2% and 10.6% more than placebo. 161 people (79%) finished. Heart rate rose 7.4 beats a minute on 0.5 mg, and blood pressure did not rise significantly on 0.25 and 0.5 mg (Astrup et al., 2008). The figures are “more than placebo,” which would put the 0.5 mg group’s total at about 11%. The trial has serious problems, covered below.
- Appetite faded. In 158 people in a phase 2 trial of the drug, a measure of fullness rose at week 12, then shrank by week 24 as weight fell. After the drug was stopped it went back to baseline, even though people were still lighter. It rose again when the drug was restarted (Gilbert et al., 2012).
- Energy burn. In 32 overweight men given 2.0 mg a day for 7 days and then 1.0 mg a day for 7 days, tesofensine produced 1.8 kg more weight loss than placebo. Total 24-hour energy expenditure was not significantly different; night-time expenditure was 4.6% higher (Sjödin et al., 2010).
- Longer follow-up. A 140-person long-term safety study is registered with no results posted (NCT00481104), and so is the 2008 trial itself (NCT00394667).
- The phase 3 trial. Saniona’s partner, Medix, ran a 24-week phase 3 trial of two strengths in 372 adults in Mexico. Saniona, the company developing the drug, reports an average loss of about 10% and says more than half of people lost 10% or more (Saniona, 2024). We found no peer-reviewed report of it and no registry entry, and no placebo result or adverse-event figures.
EvidenceCellAnimalHuman
Tesofensine with metoprolol (Tesomet)
Later trials, run by Saniona, paired tesofensine with metoprolol, a prescription drug that slows the heart. These are small, and one was in rare conditions.
| Study | Who | What happened |
|---|---|---|
| Hypothalamic obesity, 24 weeks | 21 adults whose obesity followed damage to the hypothalamus; randomized to the combination (0.5 mg tesofensine with 50 mg metoprolol) or placebo | Weight fell 6.3% more than placebo (95% CI −11.3 to −1.3); 8 of 13 on the combination lost 5% or more, against 1 of 8 on placebo. Sleep problems 50% vs 13%, dry mouth 43% vs 0, headache 36% vs 0. One serious anxiety event was judged treatment-related. No heart-rate or blood-pressure difference (Huynh et al., 2022) |
| Type 2 diabetes, 90 days | 60 adults taking 0.5 mg tesofensine with 100 mg metoprolol, or placebo; results posted on the registry, with no paper that we found | About 3.5 kg more weight loss than placebo, no difference in HbA1c, and 24-hour heart rate 3.8 beats a minute lower than on placebo (NCT02737891) |
| Prader-Willi syndrome, 12 weeks | 18 adults and adolescents taking it once a day with breakfast for 91 days (adults: 0.5 mg tesofensine with 50 mg metoprolol, or half of that); results posted on the registry | In 9 adults, weight loss was not significantly different from placebo (5.4 points more, 95% CI −12.3 to 1.5), and a score of extreme hunger improved. Three of 6 adults on the highest strength had serious adverse events (anger, hallucination, abnormal behaviour, one each), against none of 3 on placebo (NCT03149445) |
| Heart rate, phase 1 | 37 people given tesofensine 0.25, 0.5 or 0.75 mg once a day for 23 days, with a single slow-release metoprolol dose of 25, 50 or 100 mg on three later days | Tesofensine alone changed average 24-hour heart rate by −0.9, +3.5 and +7.0 beats a minute at 0.25, 0.5 and 0.75 mg. The metoprolol dose needed to cancel the rise grew with the tesofensine dose (NCT03488719) |
| Larger trials | Phase 2 studies in Prader-Willi syndrome and hypothalamic obesity | Registered, then withdrawn before enrolling anyone (NCT05198362). A 2023 review says the Prader-Willi trial was suspended in 2022 for financial reasons (Han et al., 2023) |
- Orphan status. The FDA gave the combination orphan drug designation for Prader-Willi syndrome in March 2021 and for hypothalamic obesity in July 2021 (Han et al., 2023). That designation is not approval.
- Review. A 2026 systematic review of seven trials of drugs for hypothalamic obesity found the combination reduced both body weight and lean mass, with low certainty (Yu et al., 2026).
The 2008 trial and its expression of concern
- The notice. In 2013 The Lancet published an expression of concern about the 2008 paper, the main published obesity trial of tesofensine (notice; The Lancet, 2013). The free part of the notice says the Danish Health and Medicines Authority chose completed trials for random inspection, that this one was inspected in November 2011, that concerns were raised about two of its five sites, and that the paper’s corresponding author brought them to the journal in 2012. The rest of the notice is behind a paywall, so the details below come from the sponsor’s announcement and a news report about it.
- What inspectors found. The Danish Medicines Agency inspected the trial in November 2011, at two of its five sites and at the sponsor. The sponsor said the agency found that “collection and reporting of adverse events” did not comply with the protocol and good clinical practice, and called those elements “inconclusive” (NeuroSearch, 2012).
- More detail. Retraction Watch reported that at one site consent was left to non-medical staff, that the blinding code could be read by holding sealed envelopes to a strong light, and that the research organisation recorded adverse events incompletely: conditions people already had, such as headache, migraine, stress and depression, were not reliably recorded when they recurred (Retraction Watch, 2013).
- What the sponsor and author said. The sponsor said the positive efficacy results were unchanged. The paper’s first author said the problems were at other centres and with the sponsor, that primary and secondary endpoints and serious adverse events matched source data, and that only possible under-reporting of some adverse events mattered (NeuroSearch, 2012; Retraction Watch, 2013). He and co-authors later published a letter titled “Under-reporting of adverse effects of tesofensine” (Astrup et al., 2013).
- What it means. The inspection questioned the side-effect record most. The first author says the weight and serious-event data matched source records. The 2008 side-effect list should be read as incomplete.
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Cuts weight by 10% in 24 weeks | Mixed | In the 2008 trial 0.5 mg gave 9.2 percentage points more than placebo, in a trial with an expression of concern (Astrup et al., 2008). The company reports about 10% in a phase 3 trial that has no published report (Saniona, 2024) |
| Works as well as GLP-1 drugs | Untested | Tesofensine isn’t a GLP-1 drug: it blocks reuptake of three brain chemicals (Astrup et al., 2008). No trial compared it with one. The company compares itself with them on its own page (Saniona) |
| Burns more calories | Contradicted | Total 24-hour energy expenditure was not significantly different from placebo in 32 men over 2 weeks (Sjödin et al., 2010) |
| Switches off appetite for good | Contradicted | The fullness effect shrank by week 24 and returned to baseline after the drug was stopped (Gilbert et al., 2012) |
| Has no heart effects | Contradicted | Heart rate rose 7.4 beats a minute on 0.5 mg (Astrup et al., 2008). Later trials added a beta-blocker, and the combination left 24-hour heart rate below placebo in the diabetes study (NCT02737891) |
| Won’t get you high or hooked | Mixed | In a single-dose study of 52 recreational stimulant users, tesofensine’s effects were not different from placebo and lower than amphetamine’s (Schoedel et al., 2010). We found no long-term abuse data |
| Helps ADHD or focus | Untested | We found no trial in ADHD. Its Parkinson’s trials showed no benefit in early disease (Hauser et al., 2007) |
| Is approved in Mexico | Contradicted | No. Saniona said in November 2024 that its partner had not received approval (Saniona, 2024). A regulator committee’s favorable opinion in 2023 is not approval (Saniona) |
| Is a peptide | Contradicted | No. It is a small molecule you swallow (PubChem) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
Side effects and safety
- Heart rate and blood pressure. Heart rate rose 7.4 beats a minute on 0.5 mg in 2008 (Astrup et al., 2008), and by up to 6.8 on 1.0 mg in four trials in Alzheimer’s and Parkinson’s disease (Astrup et al., 2008). A 2009 review reports significant blood pressure rises at the highest strength (Bello and Zahner, 2009).
- Common effects. Dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia in 2008 (Astrup et al., 2008). With metoprolol, sleep problems, dry mouth and headache were more common than on placebo (Huynh et al., 2022).
- Mood, anxiety and behaviour. One serious anxiety event in the hypothalamic obesity trial was judged treatment-related (Huynh et al., 2022). In the Prader-Willi study, three of six adults on the highest strength (0.5 mg tesofensine with 50 mg metoprolol) had serious anger, hallucination or abnormal-behaviour events (NCT03149445). In advanced Parkinson’s, neuropsychiatric events were more frequent than on placebo (Rascol et al., 2008), and a 2009 evaluation of the obesity trial warned it may increase psychiatric disorders (Doggrell, 2009). Those are small, unusual groups, and no published large trial has answered the question.
- Incomplete records. The adverse-event data from the 2008 trial were ruled inconclusive (NeuroSearch, 2012).
- Abuse potential. Low in a single-dose study (Schoedel et al., 2010).
- Slow to clear. With a half-life of about 10 days, effects and side effects take weeks to settle (Lehr et al., 2007).
- Unstudied. Long-term use, use in pregnancy, teens, people with heart disease, and the products sold online.
Legal and approval status
- Not approved anywhere we found. In Mexico, a regulator committee gave a favorable opinion in 2023 and the company says its application is pending (Saniona), but in November 2024 it said approval had not been received (Saniona, 2024).
- Not on the FDA’s lists. It has no entry on the FDA’s safety-risk page for compounding (FDA, 2026) or in its May 2026 compounding categories (FDA list, May 2026). Absence from those lists isn’t approval, and Drugs@FDA lists no tesofensine product (openFDA search, no match).
- Not in the October 2026 HHS policy. That temporary policy covers six peptides (Reuters, 2026).
- Banned in competition. The World Anti-Doping Agency’s 2026 list names tesofensine under S6, stimulants, which are prohibited in competition (WADA, 2026).
- Sold as a “supplement.” A 2026 doping-control study notes that it is marketed online as a dietary supplement (Krug et al., 2026). That label doesn’t make it approved.
- “Research use only” products aren’t approved for use in people.
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and registries:
- Tesofensine or Tesomet? The later trials paired tesofensine with a beta-blocker. A product listing only tesofensine is not what those trials tested (Huynh et al., 2022).
- Which form? Tesofensine is CAS 195875-84-4 and the citrate is 861205-83-6 (FDA GSRS; FDA GSRS).
- Trial numbers. A page quoting “10% weight loss” should say placebo-adjusted or not, which trial, and mention the 2013 expression of concern.
- Reviews as evidence. Customer reviews and before-and-after posts aren’t trials. They can’t show what was in the capsule.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For other compounds in this group, see GLP-1 and metabolic compounds.
What’s still unknown
- The full results of the 372-person phase 3 trial, including placebo and adverse events.
- Long-term weight, heart and mood effects beyond about a year.
- How tesofensine compares with approved weight-loss drugs in a head-to-head trial.
- Whether serious anxiety or behaviour events seen in small trials appear in larger ones.
- What is in the capsules sold online, and whether the form matches the trials.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Tesofensine. We recheck every month. Last checked Nov 11, 2026.
Flagged studies that mention Tesofensine
| Study | What it was about | Status |
|---|---|---|
| Astrup et al., 2008 | Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. | Expression of concern (2013) · notice We cite it above, with this warning. |
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Hauser et al., 2007 | Mov Disord | No retraction or concern |
| Lehr et al., 2007 | Br J Clin Pharmacol | No retraction or concern |
| Astrup et al., 2008 | Obesity (Silver Spring) | No retraction or concern |
| Rascol et al., 2008 | Arch Neurol | No retraction or concern |
| Doggrell, 2009 | Expert Opin Investig Drugs | No retraction or concern |
| Bello and Zahner, 2009 | Curr Opin Investig Drugs | No retraction or concern |
| Sjödin et al., 2010 | Int J Obes (Lond) | No retraction or concern |
| Schoedel et al., 2010 | Clin Pharmacol Ther | No retraction or concern |
| Gilbert et al., 2012 | Obesity (Silver Spring) | No retraction or concern |
| Astrup et al., 2013 | Lancet | No retraction or concern |
| Huynh et al., 2022 | Eur J Endocrinol | No retraction or concern |
| Han et al., 2023 | Gastroenterol Clin North Am | No retraction or concern |
| Perez et al., 2024 | PLoS One | No retraction or concern |
| Krug et al., 2026 | Drug Test Anal | No retraction or concern |
| Yu et al., 2026 | Obesity (Silver Spring) | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is tesofensine?
A pill that blocks the reuptake of noradrenaline, dopamine and serotonin in the brain. Weight loss showed up in its Alzheimer’s and Parkinson’s trials, so it was developed for obesity. It isn’t approved anywhere we found (Astrup et al., 2008; Astrup et al., 2008).
Is tesofensine a peptide?
No. It is a small molecule, with no chain of amino acids (PubChem).
Does tesofensine actually work?
In a 24-week trial it cut weight 9.2 percentage points more than placebo at 0.5 mg, but that trial carries an expression of concern (Astrup et al., 2008). A larger phase 3 trial has been reported only by the company (Saniona, 2024).
How much weight do you lose on tesofensine?
In the 2008 trial, 4.5%, 9.2% and 10.6% more than placebo at 0.25, 0.5 and 1.0 mg over 24 weeks, with placebo losing 2.0% (Astrup et al., 2008). The company reports about 10% in a phase 3 trial (Saniona, 2024).
Is tesofensine a GLP-1?
No. GLP-1 drugs copy a gut hormone. Tesofensine blocks reuptake of noradrenaline, dopamine and serotonin (Astrup et al., 2008). No trial has compared them.
Does tesofensine get you high?
In a single-dose study of 52 recreational stimulant users, its effects weren’t different from placebo and were lower than amphetamine’s (Schoedel et al., 2010). We found no long-term data.
What does tesofensine do for you?
It reduces appetite and raised fullness early in trials, though the effect shrank over 24 weeks (Gilbert et al., 2012). It raises heart rate (Astrup et al., 2008).
What are the side effects of tesofensine?
Dry mouth, nausea, constipation, diarrhoea, insomnia and a higher heart rate in trials (Astrup et al., 2008). Small trials also reported anxiety and behaviour events (Huynh et al., 2022; NCT03149445).
Is tesofensine safe?
We don’t know long term. The adverse-event data from the main obesity trial were ruled inconclusive (NeuroSearch, 2012), and the phase 3 safety data aren’t public.
Is tesofensine FDA approved?
No. Drugs@FDA lists no tesofensine product, and it isn’t on the FDA’s safety-risk list or compounding categories (openFDA search, no match; FDA, 2026; FDA list, May 2026).
Is tesofensine legal?
It has no approval we found. It is sold online as a supplement or research chemical, and it is banned in competition in sport (Krug et al., 2026; WADA, 2026). Our guide to what to look for covers the routes people use.
What is the tesofensine half-life?
About 234 hours, roughly 10 days, in a model from Alzheimer’s trial data (Lehr et al., 2007).
Is tesofensine used for ADHD?
We found no trial of tesofensine in ADHD.
What is the tesofensine dosage?
The 2008 trial tested 0.25, 0.5 and 1.0 mg once a day for 24 weeks (Astrup et al., 2008). The Tesomet trials used 0.5 mg of tesofensine with 50 or 100 mg of metoprolol (Huynh et al., 2022; NCT02737891). No study has set a dose for use outside a trial, and we don’t give dosing advice.
Tesofensine vs semaglutide: which is better?
No trial compared them. Semaglutide is an approved GLP-1 drug with large trials; tesofensine is unapproved and works differently (Astrup et al., 2008).
Sources
- Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-13. PubMed 18950853
- Expression of concern: effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet. 2013;381(9873):1167. PubMed 23561987; Lancet page
- Astrup A, et al. Under-reporting of adverse effects of tesofensine. Lancet. 2013;382(9887):127. PubMed 23849924
- Astrup A, et al. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 2008;16(6):1363-9. PubMed 18356831
- Hauser RA, et al. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease. Mov Disord. 2007;22(3):359-65. PubMed 17149725
- Rascol O, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch Neurol. 2008;65(5):577-83. PubMed 18474731
- Gilbert JA, et al. The effect of tesofensine on appetite sensations. Obesity (Silver Spring). 2012;20(3):553-61. PubMed 21720440
- Sjödin A, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34(11):1634-43. PubMed 20479765
- Schoedel KA, et al. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010;88(1):69-78. PubMed 20520602
- Huynh K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687-700. PubMed 35294397
- Yu H, et al. Body composition and lifestyle interventions in pharmacological treatment of acquired hypothalamic obesity: a systematic review of randomized controlled trials. Obesity (Silver Spring). 2026;34(9):1687-98. PubMed 42644866
- Han JC, et al. Management of monogenic and syndromic obesity. Gastroenterol Clin North Am. 2023;52(4):733-50. PubMed 37919024
- Krug O, Thomas A, Thevis M. Investigations into the metabolism and elimination of tesofensine in human urine. Drug Test Anal. 2026;18(9):1163-73. PubMed 42320973
- Lehr T, et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer’s disease. Br J Clin Pharmacol. 2007;64(1):36-48. PubMed 17324246
- Perez CI, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS One. 2024;19(4):e0300544. PubMed 38656972
- Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009;10(10):1105-16. PubMed 19777399
- Doggrell SA. Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13. Expert Opin Investig Drugs. 2009;18(7):1043-6. PubMed 19548858
- NeuroSearch A/S. NeuroSearch advises of the Danish Medicines Agency’s conclusion on the TIPO-1 tesofensine study inspection. Company announcement, June 22, 2012. Announcement
- Oransky I. Trial irregularities earn Lancet study of potential weight loss drug tesofensine expression of concern. Retraction Watch, April 9, 2013. Article
- Saniona. Mexican application for tesofensine not yet approved. Company release, November 6, 2024. Release
- Saniona. Tesofensine. Company page
- ClinicalTrials.gov. Tesofensine studies, searched November 11, 2026, including NCT00394667, NCT02737891, NCT03149445, NCT03488719 and NCT05198362. Search
- U.S. Food and Drug Administration. Drugs@FDA data via openFDA, searched November 11, 2026: no tesofensine product or label. openFDA search, no match
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
- World Anti-Doping Agency. 2026 Prohibited List, section S6. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: TESOFENSINE (UNII BLH9UKX9V1). GSRS
- U.S. Food and Drug Administration. Global Substance Registration System: TESOFENSINE CITRATE (UNII 3R9T98ZB7U). GSRS
Last reviewed Nov 11, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.